{
    "ticker": "RVNC",
    "name": "Revance Therapeutics, Inc.",
    "description": "Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings that leverage its proprietary DaxibotulinumtoxinA injection platform. Founded in 2013 and headquartered in Nashville, Tennessee, Revance is committed to providing exceptional products that enhance patient experiences and outcomes. The company's flagship product, DaxibotulinumtoxinA, is a next-generation neuromodulator that is transforming the landscape of aesthetic treatments by offering longer-lasting results compared to traditional options. Additionally, Revance is advancing its portfolio with a range of other products for both aesthetic and therapeutic applications, including the RHA\u00ae Collection of resilient hyaluronic acid fillers, which are designed to adapt to facial dynamics and provide natural results. With a strong focus on research and development, Revance is also exploring opportunities in various therapeutic areas, including chronic pain and migraine treatments. The company's mission is to lead the way in innovation in the biotechnology space, providing solutions that empower both healthcare providers and patients. Revance aims to create a positive impact on the quality of life for individuals seeking aesthetic enhancements and effective therapeutic treatments.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Nashville, Tennessee, USA",
    "founded": "2013",
    "website": "https://www.revance.com",
    "ceo": "Dan Browne",
    "social_media": {
        "twitter": "https://twitter.com/RevanceTx",
        "linkedin": "https://www.linkedin.com/company/revance-therapeutics/"
    },
    "investor_relations": "https://ir.revance.com",
    "key_executives": [
        {
            "name": "Dan Browne",
            "position": "CEO"
        },
        {
            "name": "Megan H. J. Dyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Aesthetic Products",
            "products": [
                "DaxibotulinumtoxinA",
                "RHA\u00ae Collection of Fillers"
            ]
        },
        {
            "category": "Therapeutic Products",
            "products": [
                "Chronic Pain Treatments",
                "Migraine Treatments"
            ]
        }
    ],
    "seo": {
        "meta_title": "Revance Therapeutics, Inc. | Innovative Aesthetic and Therapeutic Solutions",
        "meta_description": "Discover Revance Therapeutics, Inc., a leader in biotechnology focused on innovative aesthetic and therapeutic products. Explore our proprietary DaxibotulinumtoxinA and RHA\u00ae fillers.",
        "keywords": [
            "Revance",
            "Biotechnology",
            "Aesthetic Treatments",
            "DaxibotulinumtoxinA",
            "RHA Fillers",
            "Chronic Pain",
            "Migraine Treatments"
        ]
    },
    "faq": [
        {
            "question": "What is Revance known for?",
            "answer": "Revance is known for its innovative aesthetic and therapeutic products, particularly its DaxibotulinumtoxinA injection platform."
        },
        {
            "question": "Who is the CEO of Revance?",
            "answer": "Dan Browne is the CEO of Revance Therapeutics, Inc."
        },
        {
            "question": "Where is Revance headquartered?",
            "answer": "Revance is headquartered in Nashville, Tennessee, USA."
        },
        {
            "question": "What are Revance's main products?",
            "answer": "Revance's main products include DaxibotulinumtoxinA and the RHA\u00ae Collection of Fillers."
        },
        {
            "question": "When was Revance founded?",
            "answer": "Revance was founded in 2013."
        }
    ],
    "competitors": [
        "ALLERGAN",
        "IPSEN",
        "HUMACYTE"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "BMY",
        "ALNY"
    ]
}